Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
Treatment details for liver cancer are essential for patients seeking clear, evidence‑based pathways to recovery. At Liv Hospital, our international care team combines cutting‑edge technology with personalized protocols to address every stage of the disease. Each year, liver cancer accounts for more than 800,000 new cases worldwide, highlighting the urgent need for accessible, high‑quality information. This page guides you through diagnosis, surgical and non‑surgical options, systemic therapies, and the comprehensive support services that make the journey smoother for patients traveling from abroad.
Whether you are newly diagnosed or exploring second‑line options, understanding the full spectrum of available treatments empowers you to make informed decisions alongside your medical team. Our multidisciplinary approach ensures that every aspect—from imaging and pathology to post‑treatment monitoring—is coordinated seamlessly, reducing uncertainty and optimizing outcomes.
Read on to discover detailed explanations of each therapeutic modality, the criteria for selecting the most appropriate option, and the supportive infrastructure Liv Hospital provides to international patients throughout their treatment course.
Accurate staging is the cornerstone of effective treatment planning. Liver cancer is commonly classified using the Barcelona Clinic Liver Cancer (BCLC) system, which integrates tumor size, liver function, performance status, and the presence of vascular invasion or metastasis. Early‑stage disease (BCLC 0‑A) often qualifies for curative interventions, while intermediate and advanced stages (BCLC B‑C) require more complex, multimodal strategies.
Diagnostic work‑up at Liv Hospital follows international guidelines and includes:
These data feed into a multidisciplinary tumor board where hepatologists, surgical oncologists, interventional radiologists, and medical oncologists convene to define the optimal therapeutic pathway.
Understanding these stages helps patients anticipate the scope of interventions and the likely sequence of treatment details they will encounter.
When liver cancer is detected early and the patient has adequate hepatic reserve, surgical resection offers the highest chance of cure. Liv Hospital’s liver surgery team utilizes both open and laparoscopic approaches, selecting the method based on tumor location, size, and the patient’s anatomy.
Key surgical modalities include:
Pre‑operative planning incorporates 3‑D reconstruction of imaging studies, allowing surgeons to map vascular anatomy and anticipate potential complications. Post‑operative care includes intensive monitoring of liver function, pain control, and early mobilization protocols.
Outcomes at Liv Hospital demonstrate a 5‑year survival rate exceeding 60 % for patients undergoing curative resection, reflecting the institution’s expertise and comprehensive peri‑operative support.
For patients unsuitable for surgery or with intermediate‑stage disease, locoregional therapies provide tumor control while preserving healthy liver tissue. These minimally invasive procedures are performed under image guidance, often on an outpatient basis.
Major locoregional modalities include:
Selection criteria are based on tumor size, number, location, and liver function. The following table outlines typical indications:
These therapies can be combined sequentially or with systemic agents to maximize tumor response, a strategy frequently employed at Liv Hospital’s multidisciplinary tumor board.
Advanced liver cancer often requires systemic therapy to address microscopic disease and distant metastases. Over the past decade, the therapeutic landscape has expanded dramatically, moving beyond traditional cytotoxic chemotherapy to include molecularly targeted agents and immune checkpoint inhibitors.
Current systemic options include:
Therapy selection is guided by molecular profiling of tumor tissue, performance status, and liver function. Liv Hospital’s oncology pharmacists collaborate with physicians to manage side‑effects, adjust dosing, and ensure adherence.
Regular imaging (CT or MRI) every 8‑12 weeks evaluates treatment response using RECIST criteria, while blood tests monitor liver enzymes and AFP trends. This systematic approach enables timely modifications to the therapeutic plan, optimizing both efficacy and quality of life.
Effective liver cancer management hinges on coordinated care across specialties. At Liv Hospital, each patient’s case is reviewed by a dedicated tumor board that includes hepatologists, surgeons, interventional radiologists, medical oncologists, pathologists, and nursing specialists.
The multidisciplinary workflow includes:
Post‑treatment surveillance is critical for early detection of recurrence. Standard follow‑up protocol comprises:
Patients benefiting from curative resection or transplantation are enrolled in a lifelong monitoring program, ensuring prompt intervention if disease re‑emerges.
Liv Hospital’s commitment to international patients extends beyond medical care. A 360‑degree support system eases logistical challenges, allowing patients to focus on recovery.
Key support services include:
All services are coordinated through a single point of contact, ensuring seamless communication and reducing the stress associated with cross‑border healthcare.
Liv Hospital is a JCI‑accredited private facility in Istanbul, renowned for delivering world‑class cancer care to patients from around the globe. Our multidisciplinary teams employ the latest evidence‑based protocols, supported by state‑of‑the‑art technology such as robotic surgery, advanced imaging, and precision oncology platforms. International patients benefit from comprehensive logistical assistance, multilingual staff, and a compassionate environment designed to make complex treatment journeys as comfortable as possible.
Ready to discuss your personalized liver cancer treatment plan? Contact Liv Hospital’s international care team today to schedule a virtual consultation and start your journey toward recovery.
Send us all your questions or requests, and our expert team will assist you.
The Barcelona Clinic Liver Cancer (BCLC) staging system integrates four key parameters: tumor burden (size and number of nodules), liver function measured by Child‑Pugh score, patient performance status, and presence of vascular invasion or extra‑hepatic spread. It categorises patients into very early (0), early (A), intermediate (B), and advanced (C) stages, each linked to specific treatment recommendations such as curative resection for early stages or systemic therapy for advanced disease. This framework helps clinicians tailor therapy and predict prognosis.
Patients with BCLC stage 0 or A, a single tumor ≤5 cm (or up to three ≤3 cm) and preserved liver function (Child‑Pugh A/B) are ideal candidates for curative resection. The goal is complete removal of the tumor while leaving enough healthy liver tissue. Pre‑operative 3‑D imaging helps plan the extent of hepatectomy, and minimally invasive approaches (laparoscopic or robotic) can reduce postoperative pain and hospital stay. Successful resection offers the highest chance of long‑term survival, with reported 5‑year survival rates above 60 % at specialized centers.
For patients who are not surgical candidates or have intermediate‑stage disease (BCLC B), locoregional therapies aim to control tumor growth while preserving liver parenchyma. Transarterial chemoembolization (TACE) delivers chemotherapy directly to the tumor’s arterial supply followed by embolic particles to block blood flow. Transarterial radioembolization (TARE) uses Y‑90 microspheres to emit internal radiation. Ablative techniques such as radiofrequency ablation (RFA) and microwave ablation (MWA) destroy small lesions (<3‑5 cm) via heat. Stereotactic body radiation therapy (SBRT) provides precise high‑dose radiation for lesions unsuitable for ablation. Selection depends on tumor size, number, location, and liver function.
Recent phase‑III trials have established the combination of the immune checkpoint inhibitor atezolizumab with the anti‑VEGF antibody bevacizumab as the new standard first‑line therapy for unresectable hepatocellular carcinoma, offering superior overall survival compared with sorafenib. For patients who cannot receive immunotherapy, tyrosine‑kinase inhibitors (TKIs) such as sorafenib or lenvatinib remain options. Treatment choice is guided by molecular profiling, liver function, and comorbidities, with close monitoring of AFP levels and imaging every 8‑12 weeks to assess response.
After curative resection or transplantation, patients enter a lifelong monitoring program. Standard protocol includes contrast‑enhanced MRI or CT scans every three to six months during the first two years, then annually if no recurrence is detected. Serum alpha‑fetoprotein (AFP) is measured at each visit to catch biochemical signs of recurrence early. Clinical assessments evaluate liver function, nutritional status, and any symptoms suggestive of disease return. Prompt detection allows early intervention, which is critical for maintaining long‑term survival.
Your Comparison List (you must select at least 2 packages)
